The Patent Finder

Terms ending in 2033

Ambrx, Inc.

Every in-force patent on Ambrx, Inc.'s record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 9,796,754Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives
In force
 · High confidence
Ambrx, Inc.In forceHigh confidence
US 10,208,123Anti-CD70 Antibody Drug Conjugates
In force
 · High confidence
Ambrx, Inc.In forceHigh confidence
US 11,459,392ANTI-CD70 Antibody Drug Conjugates
In force
 · High confidence
Ambrx, Inc.In forceHigh confidence
US 12,037,405Anti-CD70 Antibody Drug Conjugates
In force
 · Medium confidence
Ambrx, Inc.In forceMedium confidence
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited